News | March 02, 2011

SCAI Publishes Quality Assessment Standards for Interventional Cardiology

March 2, 2011 – The Society for Cardiovascular Angiography and Interventions (SCAI) announced recommendations for assessing and improving the quality at percutaneous coronary intervention (PCI) programs at cardiac facilities. The statement, which is in the journal Catheterization and Cardiovascular Interventions, is the first document to offer guidance regarding core measures for quality and assessment in PCI programs.

In an era of health reform, defined measures of quality have become an increasingly relevant need for PCI programs. In 2005, the SCAI, in partnership with the American Heart Association and the American College of Cardiology (ACC), authored guidelines requiring all PCI facilities to evaluate performance through a continuous quality improvement (CQI) process. The SCAI and ACC have also established a catheterization laboratory accreditation program, Accreditation for Cardiovascular Excellence (ACE), designed to help standardize and track quality measures in PCI programs. ACE requires participating programs to establish a CQI process. The most recent statement better defines the established set of core quality measures and assessments for institutions with CQI programs.

“This statement demonstrates the interventional cardiology community’s dedication to upholding quality standards and continually improving patient care, including what the specific components of a quality improvement program should be,” said Lloyd W. Klein, M.D., FSCAI, professor of medicine at Rush Medical College and lead author of the statement. “It is our responsibility as the physicians who perform interventions to actively participate in developing the tools to measure and report quality outcomes, and to ensure our patients always receive the highest quality care.”

The statement emphasizes the need for every PCI program to establish a cath lab CQI committee dedicated specifically to quality performance and led by an experienced and respected interventional cardiologist. This committee’s task is to measure and assess quality based on three basic principles: the structure of the system; the processes involved for improving results and; the outcomes achieved.

In addition, it highlights multiple recommendations for evaluating PCI quality, including:

• The program must be focused on quality of care. A group of quality indicators should be established by the CQI committee based on suggested guidelines, accreditation bodies and local practice.

• Quality measures should be compared to benchmarks in recent medical literature, and participation in regional or national databases is strongly encouraged.

• A written protocol for PCI review should be developed for each committee. The process should be confidential to promote ongoing education.

• Ongoing peer-review assessment of each individual practitioner, including random case review, to assess their clinical proficiency and outcomes. Practitioners’ outcomes should also be compared against national standards and benchmark databases. The primary goal should be to improve process within the spectrum of care.

“Interventional cardiologists have been at the forefront of quality improvement in medicine for decades as we recognize the process of improving quality for the best in patient care is always evolving and we must evolve with it,” said Larry S. Dean, M.D., FSCAI, SCAI president and director of the UW Medicine Regional Heart Center and professor of Medicine and Surgery at the UW School of Medicine. “This paper is an important reference tool for interventional cardiologists to ensure quality in the cath lab.”

The document part of a two-part statement developed by SCAI to address quality assessment and improvement in interventional cardiology. The second, which is scheduled for publication in the spring of 2011, will address public reporting, risk adjustment and the role of volume as an indicator for quality of care.

For more information: www.SCAI.org

Related Content

FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
Overlay Init